Status: Recruiting
Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts
The DART-HA study is a single-center, open label, trial intended to evaluate the clinical efficacy of standard treatment options for congestive heart failure (observation, diuretic or afterload reduction therapy) in patients without new symptoms who have developed abnormalities of the HeartLogic heart failure diagnostic feature.
Participants needed: 80
Trial details
Phase: Phase 4Age: 19+Biological sex: AllType: InterventionalSponsor: Heart Center Research, LLCUpdated: Jan 29, 2024Locations: 1
Eligibility criteria
Boston Scientific device with HeartLogic enabled [+8]
Glomerular filtration rate <25 mL/min who are non-responsive to diuretic therapy... [+9]